Biodesix Inc. reported first‑quarter 2026 revenue of $25.6 million, a 42% year‑over‑year increase driven by a 29% rise in test volumes and a 99% jump in Development Services revenue. Diagnostic Testing revenue reached $22.3 million, while Development Services generated $3.3 million, reflecting a near‑doubling of the segment’s contribution to top line growth.
Gross margin expanded to 84% on a reported basis, but excluding a one‑time $0.4 million recovery the margin was 82%, a 300‑basis‑point improvement over the prior year. The lift is attributed to higher Diagnostic Testing volumes, an improved average revenue per test, and ongoing optimization of laboratory workflows that lowered the cost per test.
The company posted a GAAP earnings per share of –$0.81, beating consensus estimates of –$1.13 by $0.32. Net loss narrowed to $7.8 million from $11.1 million in Q1 2025, and adjusted EBITDA loss fell to $4.1 million from $6.2 million, reflecting stronger operating leverage and cost discipline.
Management raised its full‑year 2026 revenue outlook to $108–$114 million, up from the prior $106–$112 million range. "Following the strong first‑quarter performance and improved visibility into demand and execution, we are raising our full‑year revenue guidance to $108 million to $114 million," CFO Robin Harper Cowie said. The guidance increase signals confidence in sustained demand and the company’s ability to convert growth into profitability.
"Biodesix delivered exceptional first‑quarter results that reflect strong momentum across both our Diagnostic Testing and our Development Services business. Test volumes grew 29%, Development Services revenue doubled, and average revenue per test increased through expanded payer coverage and improved revenue cycle management, driving total revenue growth of 42% year over year," CEO Scott Hutton said. The comments underscore the company’s focus on execution and operational leverage.
The results were well received by analysts, with William Blair upgrading Biodesix to Outperform from Market Perform, citing the earnings beat and the raised guidance as evidence of strong execution and a favorable competitive position.
Headwinds remain in the form of reinvestment in commercial capacity, which is driving higher operating expenses, but the company’s margin expansion and growing primary‑care penetration provide a tailwind that supports its path to profitability.
Biodesix’s Q1 2026 performance demonstrates accelerating revenue growth, improving margins, and a narrowing loss, positioning the company closer to adjusted EBITDA positivity and reinforcing management’s confidence in the long‑term trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.